in new markets - Fresenius Medical Care

for further growth - Fresenius Kabi

for better health - Fresenius Helios

for greater efficiency - Fresenius Vamed

Seizing opportunities > in new markets

Asia is an important growth market for Fresenius Medical Care. Approximately 620,000 patients with chronic kidney failure are currently being treated in this region, and every year this number increases by about 10 to 11%. We will continue to take advantage of this growth potential. The significant demand for dialysis services offers substantial opportunities to expand our network of clinics in the Asian countries.

In 2008, Fresenius Medical Care achieved sales of US$ 606 million in the Asia-Pacific region. Our goal is to continue our strong organic growth and to increase sales to more than US$ 800 million in constant currency by 2010.

FRESENIUS MEDICAL CARE IN ASIA
	2008	2007	Change
Sales (in million US$)	606	541	12%
Employees (December 31)	3,558	3,095	15%
Dialysis patients (December 31)	9,158	7,789	18%
Dialysis treatments (million)	1.34	1.21	11%
Dialysis clinics (December 31)	125	105	19%

in new markets - Fresenius Medical Care

Seizing opportunities > for further growth

With the acquisition of APP Pharmaceuticals, Fresenius Kabi has achieved a leading position in the global market for intravenously administered generic drugs. APP Pharmaceuticals has a strong drug registration portfolio pending and over 70 products under development, opening up new growth opportunities.

At the same time, we are seizing the opportunity of introducing selected Kabi products into the US, with initial focus on parenteral nutrition. We are also planning to launch selected APP IV drugs outside the US.

APP PHARMACEUTICALS IN FIGURES
	2008
Sales	US$ 777 million
EBITDA, adjusted*	US$ 317 million
EBITDA margin, adjusted*	40.8%
Employees (December 31, full-time equivalent)	1,487
Production facilities	3
Produkte	>100
Number of products	~17%

Seizing opportunities > for better health

At Fresenius Helios, our commitment is to provide the highest medical quality and care. We aim to offer advanced and proven best-in-class diagnosis and treatment methods for the benefit of our patients. We continuously invest in high-quality, state-of-the-art medicine, and aim to measure and improve the quality of medical care.

Our target ist that our quality indicators should be better than the German average. With a mortality rate of SMR < 1, this was accomplished, among others, for major illnesses shown below.

HELIOS QUALITY INDICATORS
Indications/ standardized mortality rate (SMR)*	2008 SMR	2007 SMR
Acute myocardial infarction	0.73	0.79
Heart failure	0.73	0.85
Stroke	0.83	1.01
Acute cerebral infarction	0.81	0.99
Pneumonia	0.71	0.85

Seizing opportunities > for greater efficiency

Fresenius Vamed is a leading international provider of services in the planning, construction, and management of health care facilities. Our complete value chain and our more than 25 years of international experience are key to providing effective support for hospitals at every stage of their life cycle, and thus contributing towards their successful operating performance. For us, each project is another opportunity to prove our competence.

Hospitals face the dual challenge of increasing efficiency and reducing expenditure. We support hospitals by offering comprehensive process know-how and by taking over medical-technical services and management functions.

VAMED SERVICES

Service contracts* for	140 clinics
	~ 50,000 beds
among others:
Vienna General Hospital and University Clinics (AKH)	~ 2,100 beds
Charité Hospital Berlin	~ 3,200 beds
University Clinic Hamburg-Eppendorf	~1,370 beds
Prince Court Medical Center, Kuala Lumpur	~ 330 beds
Al Ain Hospital, Abu Dhabi	~ 450 beds

READ MORE ABOUT FRESENIUS VAMED >>

for greater efficiency - Fresenius Vamed

Fresenius Group

Home

Fresenius Group

Business Segments

Fresenius Kabi

Page 1 of 4

Fresenius Kabi had an outstanding year in 2008. Once again we saw strong sales and earnings growth. The acquisitions of APP Pharmaceuticals and Dabur Pharma marked two important advances in our progress toward global market leadership in intravenously administered generic drugs.

Fresenius Kabi specializes in the therapy and care of chronically and critically ill patients, providing clinical nutrition, infusion therapies, and related medical devices. Our products cover the total range for patient care: emergency cases, during surgery, intensive care, hospital wards, and outpatient care.

For infusion therapy, we provide infusion solutions, blood volume replacement products, and intravenously administered generic drugs such as antibiotics, anesthetics, analgesics, and drugs for the treatment of oncological diseases and critically ill patients. For the administration of these therapies, we provide infusion technologies and disposables.

For transfusion technology, we offer a range of products used by blood banks and blood donation units to produce blood products.

For clinical nutrition, we supply parenteral and enteral nutrition products. To administer these products, we offer a wide range of nutrition pumps and disposables.

BUSINESS DEVELOPMENT

In 2008, Fresenius Kabi increased sales by 23% to € 2,495 million (2007: € 2,030 million). Excellent organic growth of 9% was achieved. Net acquisitions had an impact of 16%, including the APP Pharmaceuticals and Dabur Pharma acquisitions, both of which were consolidated as from September 1, 2008. Currency translation had a negative impact of 2% on sales, mainly due to the depreciation of the currencies in Great Britain, South Africa and Korea.

The sales growth by region was as follows:

in million €	2008	2007	Change
Germany	435	434	0%
Europe (ex Germany)	1,064	930	14%
Asia-Pacific	381	311	23%
North America	336	121	178%
Latin America	184	143	29%
Other regions	95	91	4%
Total	2,495	2,030	23%

We increased sales in all regions. In Europe (excluding Germany), we achieved organic growth of 7%. In Germany, organic growth was 3%. We again reached record rates of organic growth outside Europe, with growth of 21% in Asia-Pacific, 14 % in Latin America. The increase in sales in North America is due to the initial consolidation of APP Pharmaceuticals.

1 of 4
- 1 2 3 4

1 of 4
- 1 2 3 4